首頁 > 市場調查報告書 > 製藥

疫苗動物用醫藥

市場調查報告書

商品編碼

1736517

全球新城疫疫苗市場規模（依疫苗類型、品種、區域範圍和預測）

Global Newcastle Disease Vaccine Market Size By Vaccine Type (Live Attenuated, Inactivated & Thermostable), By Species (Chicken, Duck & Goose), By Geographic Scope And Forecast

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

新城疫疫苗市場規模及預測

2024 年新城疫疫苗市場規模為 2.8927 億美元，預計到 2032 年將達到 3.7216 億美元，2026 年至 2032 年的複合年成長率為 3.20%。

新城疫是由禽副黏液病毒1型（APMV-1）引起的一種嚴重的禽類病毒性疾病。此病傳染性極強，可感染多種家禽，包括雞和火雞，其中母雞尤其易感。該病毒透過糞口途徑傳播，這意味著鳥類可能透過攝入受污染的糞便、食物、飲料或與病禽接觸過的設備而感染。

根據美國國家醫學圖書館的數據，在2-3週齡時透過氣霧劑接種活體新城疫病毒（NDV）活病毒疫苗的商用火雞，通常不會產生高或持續的血清抗體滴度（血凝抑制試驗檢測結果）。接種疫苗的火雞在接種2週後通過眼鼻或氣霧劑途徑進行攻擊時，對感染和臨床疾病具有良好的抵抗力，在接種6週後再次攻擊時，對臨床疾病也具有抵抗力，但保護水平在接種10週後下降。

這些結果表明，可能需要兩次或兩次以上 NDV 噴霧疫苗接種才能完全保護在 NDV 流行環境中飼養的正在發育的火雞免受自然 NDV 感染。

禽類嚴重呼吸窘迫和神經病變率的不斷上升，推動了新城疫疫苗市場的大幅擴張。該疾病發病率的不斷上升、對食用牲畜的需求的不斷成長，以及對該疾病治療方法的持續研究，預計將推動市場擴張。隨著人們越來越意識到保持健康的益處，消費者對優質醫療服務的需求不斷成長，新城疫疫苗市場也不斷擴大。

新城疫疫苗市場動態

影響全球新城疫疫苗市場的關鍵市場動態是：

關鍵市場促進因素

疾病爆發：雞新城疫 (ND) 在家禽群體中的存在是新城疫疫苗產業發展的主要動力。隨著 ND 持續影響全球家禽養殖場，對有效預防疾病傳播的疫苗需求龐大。

家禽業的成長：受全球對肉類和蛋類等家禽產品需求不斷成長的推動，家禽業的擴張也推動了新城疫疫苗市場的發展。隨著雞肉產量的增加和向新地區的擴展，對綜合疫苗接種計劃的需求也日益成長。

環境與生物安全問題：人們對生物安全以及疾病爆發對環境影響的擔憂日益加劇，促使人們採取疫苗接種等預防措施。積極主動地預防新城疫，既能保護環境，又能確保養雞生產系統的長期永續性。

疾病爆發：新城疫疫情導致疫苗接種力道加大，尤其是在家禽產區，並催生了新城疫疫苗的市場需求。疫情爆發會對家禽生產者造成重大經濟損失，因此有效疫苗接種工作至關重要。

主要問題

成本限制：新城疫疫苗的高成本阻礙了其推廣，尤其是在資源有限的小規模家禽養殖戶。開發經濟的疫苗配方並採用經濟有效的疫苗接種方法，對於該疾病的廣泛接受和控制至關重要，尤其是在低收入國家。

生物安全意識不斷提升：隨著新城疫疫情的爆發日益普遍且大規模，農民逐漸意識到生物安全措施對保護雞群的重要性。疫苗接種是生物安全措施的關鍵組成部分，推動了新城疫疫苗的需求。

新株的出現：新城疫病毒不斷變異，導致出現新的、更具侵襲性的病毒株。這些新株可能導致現有疫苗失效，因此需要開發新的改良疫苗，而這既耗時又耗資。

疫苗取得管道有限。一些較貧窮的國家取得獸用疫苗（例如新城疫疫苗）的機會有限。這歸因於多種因素，包括基礎設施不足、資金不足和意識缺乏。這些國家的農民在保護牲畜免受新城疫侵害方面選擇較少。

主要趨勢

家禽產品需求不斷增加：全球人口對雞肉和雞蛋的需求不斷成長，導致雞肉產量增加。這導致對疫苗的需求增加，以保護家禽免受新城疫的爆發。新城疫會導致雛雞死亡並造成巨大的經濟損失。

不斷加深對新城疫經濟影響的認知：家禽生產者越來越意識到新城疫可能造成的經濟損失，包括禽類死亡、產蛋量下降以及貿易限制。疫苗接種被認為是預防這些損失的一種經濟有效的方式。

疫苗接種技術的進步：正在進行研究和開發，以開發更有效、更耐熱的新城疫疫苗，這將有助於疫苗的儲存和分發，這在冷藏條件有限的地區尤其重要。

政府立法和疫苗接種計劃：許多政府已經採取了針對雞的新城疫強制疫苗接種計劃，以幫助減少疾病的傳播，同時保護家禽養殖企業。

Newcastle disease is a severe viral sickness in birds caused by avian paramyxovirus type 1 (APMV-1). It is very contagious and can spread too many domestic birds, including chickens and turkeys, with hens being especially vulnerable. The virus is spread by the fecal-oral route, which means that birds become infected after consuming contaminated droppings, food, drink, or equipment that has come into contact with sick birds.

According to National Library of Medicine, Commercial market turkeys spray-vaccinated at 2 to 3 weeks of age with live Newcastle disease virus (NDV) vaccine did not often generate high or persistent serum antibody levels as detected by the hemagglutination-inhibition test. Vaccinated turkeys demonstrated adequate resistance to infection and clinical disease when challenged by the oculonasal or aerosol route at 2 weeks post-vaccination, and they resisted clinical disease when challenged at 6 weeks, but the level of protection decreased by 10 weeks post-vaccination.

It is proposed that market turkeys raised in an NDV-enzootic environment may require two or more NDV spray vaccinations during their developing phase in order to be fully protected against natural NDV infection.

The increasing incidence of severe respiratory distress and nervous difficulties in birds contributes to the huge expansion of the Newcastle Disease Vaccine Market. Expanding outbreaks of the disease, expanding demand for livestock for food, and continuous research to produce a treatment for this disease are expected to drive market expansion. The Newcastle Disease Vaccine Market is thriving as people become more aware of the benefits of maintaining good health, resulting in a greater demand for high-quality healthcare services among consumers.

Newcastle Disease Vaccine Market Dynamics

The key market dynamics that are shaping the global Newcastle disease vaccine market include:

Key Market Drivers:

Disease Prevalence: The presence of Newcastle disease (ND) in poultry populations is a major driver of the Newcastle disease vaccine industry. As ND continues to affect poultry farms around the world, there is a great demand for effective vaccines to prevent the disease from spreading.

Growth of the Poultry Industry: The expansion of the poultry industry, fueled by rising global demand for chicken products such as meat and eggs, helps to drive the Newcastle disease vaccine market. As chicken production increases and spreads into new areas, the necessity for comprehensive immunization programs becomes increasingly pressing.

Environmental and Biosecurity Concerns: Growing concern about biosecurity and the environmental impact of disease outbreaks is driving the use of preventive measures like immunization. Proactive steps to avoid Newcastle disease can save the environment while also ensuring the long-term viability of chicken production systems.

Disease Outbreaks: Newcastle disease outbreaks, particularly in poultry-producing regions, lead to intensified immunization efforts and generate market demand for Newcastle disease vaccines. Outbreaks can cause large economic losses for poultry producers, highlighting the significance of effective vaccination efforts.

Key Challenges:

Cost Constraints: The high cost of Newcastle disease vaccines can deter adoption, especially among small-scale chicken breeders with limited financial resources. Developing economical vaccine formulations and adopting cost-effective immunization procedures is critical for ensuring widespread acceptance and disease control particularly in low-income nations.

Increased Biosecurity Awareness: As Newcastle disease outbreaks become more common and extensive, farmers recognize the significance of biosecurity measures to protect their flocks. Vaccination is a critical component of biosecurity measures, which is boosting the demand for Newcastle disease vaccine.

Emergence of New Strains: The Newcastle disease virus is constantly mutating, with new and more aggressive strains appearing. These novel strains may render current vaccines ineffective, prompting the creation of new and improved vaccines. This can be a long and costly process.

Limited Access to Vaccines: Some impoverished countries have limited access to veterinary vaccines, such as Newcastle disease vaccines. This is due to a variety of issues, including inadequate infrastructure, money, and awareness. Farmers in these nations have fewer options for protecting their animals from Newcastle disease.

Key Trends:

Rising Demand for Chicken Products: The global population's expanding appetite for poultry meat and eggs has resulted in increased poultry production. This increases the need for immunization to protect birds from Newcastle disease outbreaks, which may kill chicks and result in considerable economic losses.

Increasing Knowledge of Newcastle Disease's Economic Impact: Poultry growers are becoming more conscious of the financial losses caused by Newcastle disease. This includes avian mortality, reduced egg output, and trade restrictions. Vaccination is viewed as a cost-effective method of preventing these losses.

Advances in Vaccination Technology: Research and development are underway to build more effective and thermostable Newcastle disease vaccines. This is especially significant in areas with limited refrigeration access, as it facilitates vaccine storage and distribution.

Government Laws and Immunization Programs: Many governments have adopted mandatory vaccination programs against Newcastle disease in chicken. This helps to control disease spread while also protecting the poultry business.

Global Newcastle Disease Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Newcastle disease vaccine market:

North America:

The Newcastle disease vaccine market, owing to a robust chicken sector and high demand for poultry products, including meat and eggs. The region's chicken industry is well-established, but Newcastle disease poses ongoing challenges needing stringent preventive measures such as immunization. This need emphasizes the importance of Newcastle disease vaccines in protecting the region's poultry stock and assuring the continuation of its thriving poultry market.

Furthermore, North America's unwavering dedication to sustainable agriculture techniques and animal welfare encourages the use of Newcastle disease vaccines. Prioritizing poultry health and well-being demonstrates the region's commitment to sustaining high food safety and animal care standards, which resonates positively with both consumers and industry stakeholders.

North America's dominant market position not only represents its enormous contribution to the global Newcastle disease vaccine market, but also demonstrates its unwavering commitment to safeguarding the poultry industry's viability and resilience in the face of evolving disease threats.

Asia Pacific:

The Asia-Pacific region is expected to lead the Newcastle disease vaccine market, as it is home to some of the world's top poultry producers, including China, India, and Indonesia. Here, rising demand for poultry products, fueled by population growth and changing dietary habits, drives the need to protect poultry flocks from Newcastle disease outbreaks. As a result, there is a significant increase in demand for vaccines, emphasizing the importance of preventive measures in supporting the region's thriving poultry sector.

Furthermore, the Asia-Pacific area is experiencing tremendous development in the poultry business, as well as increased knowledge of biosecurity regulations. This double momentum not only strengthens the Newcastle disease vaccine market but also demonstrates the region's proactive approach to disease prevention in chicken production. These factors firmly position Asia-Pacific as a key catalyst for Newcastle disease vaccine market growth, demonstrating its critical role in maintaining the global poultry industry's resilience in the face of changing challenges.

Europe:

The European market is primed to emerge as a serious competitor, boosted by proactive government programs that assist research and development efforts, particularly in the field of Newcastle disease vaccines. With significant investments in improving veterinary science and tight regulatory frameworks, the region creates an atmosphere conducive to innovation in animal health solutions.

Furthermore, Europe's significant advancements in animal husbandry procedures strengthen its position in the Newcastle disease vaccine market. By embracing innovative techniques and technology aimed at improving animal welfare and disease prevention, the region demonstrates its commitment to upholding high animal health and food safety standards. This combination of government funding, scientific excellence, and modern husbandry techniques puts Europe as a major player set to make great advances in the international Newcastle disease vaccine market.

Global Newcastle Disease Vaccine Market: Segmentation Analysis

The Global Newcastle Disease Vaccine Market is segmented on the basis of Vaccine Type, Species, And Geography.

Newcastle Disease Vaccine Market, By Vaccine Type

Live Attenuated
Inactivated
Thermostable

Based on Vaccine Type, the market is divided into Live Attenuated, Inactivated and Thermostable. The Live Attenuated Vaccines (LAV) segment dominated the market in 2022 and is expected to have the highest compound annual growth rate (CAGR) over the forecast period. LAVs have remained popular among poultry breeders due to their effectiveness, low cost, and potential to provide long-term immunity. These vaccines have demonstrated efficacy against many strains of Newcastle disease viruses and provide broad-spectrum protection.

Newcastle Disease Vaccine Market, By Species

Chicken
Duck
Goose

Based on Species, the Newcastle disease vaccine market is segmented Chicken, Duck and Goose. The chicken sector grabbed the biggest market share and is expected to retain a significant compound annual growth rate (CAGR) over the projection period. Newcastle Disease Virus (NDV) is a major threat to the poultry industry, causing significant economic losses. As a result, the demand for Newcastle Disease Vaccines remains high among chicken farmers, making this segment the most profitable in the market.

Newcastle Disease Vaccine Market, By Geography

North America
Europe
Asia Pacific
Rest of the World
On the basis of regional analysis, the Global Newcastle Disease Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share of Newcastle disease vaccine followed by Europe. Growing demand for effective emergency care and increasing adoption of mobile surgery centers are anticipated to drive the industry during the forecast period.

Key Players

The "Global Newcastle disease vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merial, QYH Biotech, CEVA, Yebio, Ringpu (Tianjin) Bio-Pharmacy Co. Ltd,Bayer AG, Hipra, Anicon Labor GmbH, Chengdu Tech-bank Biological Products Co. Ltd., Ringpu Bio-Technology Co. Ltd., MSD Animal Health, Nisseiken Co., Harbin Veterinary Research Institute, Merck Animal Health, ChengDu Tecbond, DHN, Zoetis, Elanco (Lohmann), CAVAC, Vaksindo, FATRO. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Newcastle Disease Vaccine Market Recent Developments
In June 2022, Ceva Sante bought Canadian firm Artemis Technologies, Inc. to extend its oral rabies vaccine line. Ceva's North American presence will be expanded as a result of this transaction.
In April 2020, The Indian Institute of Technology Guwahati and Hester Biosciences cooperated to create a new coronavirus vaccine (COVID-19). The vaccine is based on a recombinant avian paramyxovirus vector platform.

1 INTRODUCTION OF GLOBAL NEWCASTLE DISEASE VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL NEWCASTLE DISEASE VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY VACCINE TYPE

5.1 Overview
5.2 Live vaccines
5.3 Killed vaccines

6 GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY SPECIES

6.1 Overview
6.2 Chicken
6.3 Duck and goose
6.4 Others

7 GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East and Africa

8 GLOBAL NEWCASTLE DISEASE VACCINE MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Merck Animal Health
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 GALVmed
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Elanco
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Boehringer Ingelheim
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 QYH Biotech
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Ceva Animal Health LLC
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Hester Biosciences Limited
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Zoetis, Inc.
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 CAVAC
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments